This company has been quietly innovating the way infectious diseases are diagnosed and is set to tap into a multi-billion dollar industry demand. With only 2% of the Australian market, the company took in almost $2M in revenue with a 92% compound annual growth rate. So what is it worth if it moves to 10% of the Australian market and starts picking up US sales too?
What if it starts to get toward 2% of the US market in the next year or so? That might mean a revenue in the order of $10M plus. This is a future $300m market cap company that is just starting to book revenue, increase sales, increase products, increase market share.
Time to take an interest in this one.
R
GSS Price at posting:
48.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)